Research
Awards Grant
A Phase 1 / 2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia
A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum
A Phase I Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA) in Children with Relapsed Refractory Solid Tumors
A Phase II Study of Sunitinib in Recurrent or Progressive Brain Tumors in Pediatric and Young Adult Patients
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders/ PBMTC PIDTC #6901
A Study of the Genetic Causes of Latent Autoimmune Diabetes in Adults
AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,
AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia
AALL0434-Novartis Pharmaceuticals Corporation
AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)
AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases
AAML 1031 - Bayer
AAML1031: One Time EOY, Integrated BIQSFP AAML1031-Echocardiogram Reports and Images
ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents
AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.
AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
ALTE11C2 Study - Health Effects after Antracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy
ALTE11C2 Study - Health Effects after Antracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy
ALTE11C2 Study – Health Effects After Antracycline and Radiation Therapy (HEART) – Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy
ALTE11C2-Health Effects after Anthracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy
ALTE1621, Reducing Risk of Anthracycline-Related Heart Failure after Childhood Cancer
ALTE1631, A Randomized Web-Based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
ANBL1531: A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement
CA 180-372, AALL1122 A Phase 2, Multi-Center, Historically Controlled Study of Dasatinib added to Standard Chemotherapy for Relapsed/Refractory Ph+ALL
CCOP Per Case Reimbursement
CHOP NCORP - COG Study Chair
CHOP NCORP - COG Study Chair
CHOP NCORP - COG Study Chair
CHOP NCORP Research Base
CHOP Scientific Council
CHOP Scientific Council
CHOP Scientific Council Chair Grant
CHOP Scientific Council Chair Grant
CHOP Scientific Council Chair Grant
CHOP Work Order for STUDY: AALL 1521
COG Nursing Discipline Strategic Planning Meeting
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
COG Per Case Reimbursement
CTSU: Phase II Supplemental Payments (N02-CM-62212)
CTSU: Phase ll Supplemental Payments (N02-CM-62212)
Children's Oncology Group Chair's Grant
Children's Oncology Group Chair's Grant
Children's Oncology Group NCTN Network Group Operations
Children's Oncology Group NCTN Network Group Operations
Children’s Brain Tumor Tissue Consortium (CBTTC)
Committee Leadership: NIH National Clinical Trials Network Grant
Committee Leadership: NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Acute Myeloid Leukemia Steering Committee
Committee Leadership: NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Adolescent-Young Adult Committee Young Investigator
Comparative Effectiveness of Therapy for Enthesitis-Related Arthritis
Cookies for Kids' Cancer Phase 1 Supplemental
Defining Disease Flare in Enthesitis-Related Arthritis Patients
Deliberate Practice to Improve Interdisciplinary Communication: A Pilot Study
Developing a Network to Utilize Administrative and Clinical Data for Childhood, Adolescent and Young Adult Oncology Survivorship Research
Development of Axial Juvenile Spondyloarthritis (AxJSpA) Classification Criteria
Distracted Driving in Teens with ADHD
Genetic Predictors of AML Treatment Response
Health Effects after Anthracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Anthracycline - related Cardiomyopathy (ALTE11C Study)
Hypothemia's Impact on Pharmacology 2
Impact of Hypothermia on Midazolam/Morphine Pharmacokinetics
Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant
(UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)
Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
Isolation of Friedreich's Ataxia Fibroblast Cell Lines
Larotrectinib for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Longitudinal, Multimodal Assessment of Neuropsychological Functioning in Children Diagnosed with High-risk Lymphoblastic Leukemia (HR-ALL); Using Early Changes to Predict Later Impairment (ALTE07C1)
NIH COG Phase I Grant
NIH COG Phase I Grant
NIH National Clinical Trials Network (NCTN) Grant (2U10CA180886) Successor to NIH National Clinical Trials Network (NCTN Grant (U10CA180886)
Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)
Pediatric Intravenous Versus Oral Antibiotic Therapy
Pediatric Palliative Care Research Network SHARE Study
Per Case Reimbursement COG NCORP Research Base
Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant
Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant
Per Case Reimbursement: COG NCORP Research Base
Per Case Reimbursement: COG NCORP Research Base
Pharmacologic Impact on Sedation Assessments (PISA)
Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
Project EveryChild APEC14B1
Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
Reduced-Intensity Conditioning for Children and Adults with Hemaphagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)
Refining Entry Criteria and Outcome Measures for Children with Axial Disease and Spondyloarthritis: Preparation for Clinical Trials
STUDY: CA180-372: PH II Pediatric - Ph+ ALL
Sacroillitis in Children with Juvenile Spondyloarthritis: Improving Diagnosis and Outcomes
Scientific Leadership NIH National Clinical Trial Network (NCTN) Grant
St. Baldrick's Foundation Supplemental Reimbursement
St. Baldricks Fdn Supplemental Reimbursement
St.Baldrick's Foundation Support: ALTE15N2 Study
Study Chair: NIH National Clinical Trials Network (NCTN) Grant (U10CA18086) Successor to NIH COG Chair Grant (U10CA098543)
The Child-Centered Outcomes in Practice and Research (COPR) Center of Excellence: Strengthing the Clinical Validity Evidence Base for PROMIS Measures in Chronically Ill Children
The Effects of Sleep Restriction on Adolescent's Pedestrian Safety
Transdisciplinary Transition LC and Longterm Registry
Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen / BMT CTN Protocol 0601
WORKLOAD INTENSITY – NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
Workload Intensity
Workload Intensity-NIH National Clinical Trials Network (NCTN) Grant (2U10CA180886) Successorto NIH National Clinical Trials Network
